insulin sensitizer

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patientuncoded clinical condition ***       biguanidePPAR modulatorthiazolidinediones aleglitazarmetforminpioglitazonerosiglitazone vs placebo or controlvs standard glucose-lowering drugsvs SU or insulinvs Sulfonylureas      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (62)myocardial infarction (fatal and non fatal) (59)stroke (fatal and non fatal) (54)Heart failure (26)all cause death, MI, stroke (24)cardiovascular events (6)Cardiovascular death (3)microvascular events (3)Any diabetes-related outcomes (2)Diabetes-related death (2)Peripheral vascular events (2)macrovascular or microvascular events (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	myocardial infarction (fatal and non fatal)
diabetes type 2
aleglitazar
ALECARDIO    NCT	aleglitazar	placebo				-
metformin
Teupe, 1991	metformin	placebo				negative
Kooy (HOME), 2009	metformin	placebo			Low risk of bias	suggesting
Campbell, 1994	metformin	Glipizide				negative
UKPDS (vs SU or INS)	metformin	SU/Insulin				suggesting
pioglitazone
EC404	pioglitazone	metformin			Exploratory	negative
EC409	pioglitazone + sulfonylurea	metformin + sulfonylurea			Exploratory	negative
PNFP-001	pioglitazone	placebo			Exploratory	negative
PNFP-026	pioglitazone	placebo			Exploratory	negative
PROactive, 2005      NCT	pioglitazone	placebo			Low risk of bias	suggesting
PNFP-012	pioglitazone	placebo			Exploratory	negative
PNFP-014	pioglitazone + insulin	placebo (add on insulin)			Exploratory	negative
OPI-502	pioglitazone + insulin	placebo (add on insulin)			Exploratory	negative
PNFP-027	pioglitazone + metformin	placebo (add on MET)			Exploratory	negative
GLAI    NCT	pioglitazone	rosiglitazone			Exploratory	negative
OPI-504    NCT	pioglitazone	sulfonylurea			Exploratory	negative
OPI-520    NCT	pioglitazone	sulfonylurea			Exploratory	negative
OPI-501	pioglitazone	sulfonylurea			Exploratory	negative
EC405	pioglitazone	sulfonylurea			Exploratory	negative
OPI-506    NCT	pioglitazone	sulfonylurea			Exploratory	negative
PNFP-010	pioglitazone + sulfonylurea	sulfonylurea			Exploratory	negative
EC410	pioglitazone + metformin	sulfonylurea + metformin			Exploratory	negative
Bolli, 2008	pioglitazone	vildagliptin				negative
PERISCOPE, 2008      NCT	pioglitazone	glimepiride			Low risk of bias	negative
rosiglitazone
SB-712753/007	rosiglitazone				Exploratory	-
AVM100264    NCT	rosiglitazone				Exploratory	-
BRL 49653C/185	rosiglitazone				Exploratory	-
SB-712753/009	rosiglitazone				Exploratory	-
Wang, 2005	rosiglitazone	control			Exploratory	-
49653/097	rosiglitazone	glyburide			Exploratory	-
49653/020	rosiglitazone	glyburide			Exploratory	-
49653/143    NCT	rosiglitazone	glyburide			Exploratory	-
49653/079	rosiglitazone	glyburide			Exploratory	-
49653/080	rosiglitazone	glyburide			Exploratory	-
49653/137    NCT	rosiglitazone	glyburide (add on MET)			Exploratory	-
49653/093	rosiglitazone	metformin			Exploratory	-
49653/094	rosiglitazone	metformin			Exploratory	-
49653/011	rosiglitazone	placebo			Exploratory	-
AVA100193	rosiglitazone	placebo			Exploratory	-
49653/331	rosiglitazone	placebo			Exploratory	-
BRL 49653/334    NCT	rosiglitazone	placebo			Exploratory	-
49653/134	rosiglitazone	placebo			Exploratory	-
49653/128	rosiglitazone	placebo			Exploratory	-
49653/136	rosiglitazone	placebo			Exploratory	-
49653/330	rosiglitazone	placebo			Exploratory	-
49653/145	rosiglitazone	placebo (add on glicazide)			Exploratory	-
49653/234	rosiglitazone	placebo (add on glimepiride)			Exploratory	-
49653/135	rosiglitazone	placebo (add on glipizide)			Exploratory	-
49653/162	rosiglitazone	placebo (add on glyburide)			Exploratory	-
100684    NCT	rosiglitazone	placebo (add on glyburide)			Exploratory	-
49653/127	rosiglitazone	placebo (add on glyburide)			Exploratory	-
49653/095	rosiglitazone	placebo (add on insulin)			Exploratory	-
BRL 49653/347    NCT	rosiglitazone	placebo (add on insulin)			Exploratory	-
49653/085	rosiglitazone	placebo (add on insulin)			Exploratory	-
712753/008    NCT	rosiglitazone	placebo (add on MET)			Exploratory	-
49653/284    NCT	rosiglitazone	placebo (add on MET)			Exploratory	-
SB-712753/002	rosiglitazone	placebo (add on MET)			Exploratory	-
SB-712753/003	rosiglitazone	placebo (add on MET)			Exploratory	-
49653/147	rosiglitazone	placebo (add on SU)			Exploratory	-
49653/132	rosiglitazone	placebo (add on SU)			Exploratory	-
49653/125    NCT	rosiglitazone	placebo (add on SU)			Exploratory	-
49653/015	rosiglitazone	placebo (add on SU)			Exploratory	-
49653/211	rosiglitazone	usual care			Exploratory	-
APPROACH, 2008        NCT	rosiglitazone	glipizide			Low risk of bias	-
RECORD, 2009          NCT	rosiglitazone	standard glucose-lowering drugs			Risk of bias	negative
ADOPT, 2006        NCT	rosiglitazone	standard glucose-lowering drugs			Low risk of bias	negative